Perioperative administration of single, high-dose of ATG-Fresenius-S as an induction immunosuppressive therapy in cadaveric renal transplantation: preliminary results

Samsel, Radosław; Rowińskí, W; Chmura, A.; Włodarczyk, Zbigniew; Wyzgał, Janusz; Cieciura, T.; Łągiewska, B; Pliszczyński, Jacek; Korczak, G.; Pączek, Leszek; Wałaszewski, J; Lao, M

doi:10.1016/s0041-1345(01)02268-0

Cited by 8 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 Indeed, numerous studies have shown similar clinical outcomes with rATG induction therapy despite widely varying dosing schemes; these include every-otherday dosing, withholding doses on the basis of absolute CD3 counts, and administering the total rATG as a 1time infusion, among others. 13,[15][16][17][18][19][20][21][22][23][24][25][26][27][28] Outpatient peripheral administration of rATG is an absolute necessity to facilitate a process such as the one presented here. Going strictly by the package insert, the use of rATG in this capacity would be considered inappropriate.…”

Section: Discussionmentioning

confidence: 99%

Clinical and Economic Analysis of Delayed Administration of Antithymocyte Globulin for Induction Therapy in Kidney Transplantation

et al. 2013

View full text Add to dashboard Cite

Patients who had delayed administration of rabbit antithymocyte globulin had shorter stays (3.9 vs 3.1 days, P< .001) and reduced inpatient costs for rabbit antithymocyte globulin (mean $860/patient); these changes were achieved without affecting acute rejection rates (5% vs 5%, P> .99) or readmission rates. In conclusion, delayed inpatient administration of rabbit antithymocyte globulin provided identical clinical outcomes while helping to reduce inpatient costs and increase timely discharges.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical and Economic Analysis of Delayed Administration of Antithymocyte Globulin for Induction Therapy in Kidney Transplantation

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The 1-year actuarial patient and graft survival were 97% and 92%, respectively. Bolus ATG was evaluated in cadaveric renal transplantation by Samsel et al [12], reporting that the rejection rate in bolus group was significantly lower than in control. No significant side effects or serious adverse events in both groups were observed.…”

Section: Discussionmentioning

confidence: 99%

Long-term evaluation of single bolus high dose ATG induction therapy for prophylaxis of rejection in live donor kidney transplantation

et al. 2007

View full text Add to dashboard Cite

show abstract

Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients

Hill

Cross

Barnett

et al. 2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

ATG reduces acute rejection but has uncertain effects on death, graft survival, malignancy and NODAT, and increases CMV infection, thrombocytopenia and leucopenia. Given a 45% acute rejection risk without ATG induction, seven patients would need treatment to prevent one having rejection, while incurring an additional patient experiencing CMV disease for every 12 treated. Excluding non-CNI studies, the risk of rejection was 37% without induction with six patients needing treatment to prevent one having rejection.In the context of steroid minimisation, alemtuzumab prevents acute rejection at 1 year compared to ATG. Eleven patients would require treatment with alemtuzumab to prevent 1 having rejection, assuming a 21% rejection risk with ATG.Triple maintenance without induction therapy compared to alemtuzumab combined with ESW had similar rates of acute rejection but adverse effects including NODAT were poorly documented. Alemtuzumab plus steroid withdrawal would cause one additional patient experiencing CMV disease for every six patients treated compared to no induction and triple maintenance, in the absence of any clinical benefit. Overall, ATG and alemtuzumab decrease acute rejection at a cost of increased CMV disease while patient-centred outcomes (reduced death or lower toxicity) do not appear to be improved.

show abstract

Perioperative administration of single, high-dose of ATG-Fresenius-S as an induction immunosuppressive therapy in cadaveric renal transplantation: preliminary results

Cited by 8 publications

References 11 publications

Clinical and Economic Analysis of Delayed Administration of Antithymocyte Globulin for Induction Therapy in Kidney Transplantation

Clinical and Economic Analysis of Delayed Administration of Antithymocyte Globulin for Induction Therapy in Kidney Transplantation

Long-term evaluation of single bolus high dose ATG induction therapy for prophylaxis of rejection in live donor kidney transplantation

Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients

Contact Info

Product

Resources

About